On February 23, 2022 Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, reported that the Company has received a payment totaling USD $750,000 from BioRay Pharmaceutical, Ltd. ("BioRay") in association with the Licensing Agreement established between the two companies in May 2021 (Press release, Nascent Biotech, FEB 23, 2022, View Source [SID1234608886]). This payment represents the Second Payment stipulated in the Licensing Agreement (the "Agreement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Agreement grants to BioRay exclusive rights to commercialize Nascent’s monoclonal antibody, Pritumumab, in international markets, excluding North America and Central America. Under terms of the Agreement, Nascent will receive a total of USD $5,000,000 to be paid out at various stipulated milestones. The initial payment of USD $1,000,000 was received by Nascent on April 20, 2021.

This second payment of USD $750,000 was received by Nascent for entering the third cohort in Nascent’s first Phase 1 clinical trial of Pritumumab.

A third payment of USD $2,500,000 will be received by Nascent upon approval from the FDA to conduct a Phase 2 clinical trial of Pritumumab. The final USD $750,000 payment will be received by Nascent upon the commencement of the Phase 2 clinical trial.

"There continue to be significant unmet medical needs across a variety of cancers," remarked Sean Carrick, CEO of Nascent Biotech. "We are highly encouraged by Pritumumab’s potential as an innovative, first-in-class treatment candidate, and we are delighted to be working closely with BioRay in this collaboration."

On February 23, 2022 Nichi-Iko Pharmaceutical Co., Ltd. has recently reported that it received approval for a biosimilar of bevacizumab BS intravenous infusion 100 mg/400 mg, whose marketing authorization application was filed based on the clinical pharmacokinetic (PK) study data conducted in Japan in addition to the global Phase 3 study data conducted by mAbxience (Press release, mAbxience, FEB 23, 2022, View Source [SID1234608885]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bevacizumab BS is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin. Bevacizumab BS is indicated for the treatment of advanced or recurrent colorectal cancer that is not curatively resectable and advanced or recurrent non-small cell lung cancer that is not resectable except for squamous cell carcinoma.

On February 23, 2022 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022 (Press release, Jounce Therapeutics, FEB 23, 2022, View Source [SID1234608884]). Jounce Therapeutics’ management team will host a live conference call and webcast at 8:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast

To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8998936. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.

On February 23, 2022 Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, reported that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update (Press release, Pieris Pharmaceuticals, FEB 23, 2022, View Source [SID1234608882]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least five minutes prior to the start of the call. Alternatively, a listen-only audio webcast of the call can be accessed here.

For those unable to participate in the conference call or listen to the webcast, a replay will be available on the Investors section of the Company’s website, www.pieris.com.

On February 23, 2022 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, reported that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies (Press release, Intellia Therapeutics, FEB 23, 2022, View Source [SID1234608881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As Intellia continues to advance a growing number of innovative CRISPR-based medicines, the ability to efficiently and reliably manufacture our products is crucial to our mission of bringing transformational medicines to patients with life-threatening diseases," said Intellia Chief Technical Officer Eliana Clark, Ph.D. "This new facility is a strategic investment, which in combination with existing capabilities and partnerships, will provide us with significant manufacturing capacity and accelerate the clinical development and future commercial production for our therapeutic candidates."

The new manufacturing facility will be Good Manufacturing Practice (GMP) compliant and support both the preclinical through commercial supply upon regulatory approval for key components of Intellia’s CRISPR-based therapies. Additionally, this new facility will be able to provide capacity and capabilities in support of Intellia’s expanding pipeline and commercial readiness.

The new facility, customized for Intellia’s requirements, will be constructed and managed by Alexandria Real Estate Equities, L.P. and is expected to be operational in 2024. Intellia Chief Financial Officer Glenn Goddard went on to comment, "Choosing a long-term lease agreement provides Intellia with greater manufacturing flexibility and only a modest financial upfront requirement compared with building our own facility from the ground up. We look forward to working with Alexandria as they build this new facility."